| |
FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
December 15, 2022
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) ("CardioComm" or the "Company"), a leading global medical provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, \
a global provider of consumer heart monitoring and electrocardiogram (("ECG") device and software solutions,
confirms a technology integration agreement with Utah-based CareXM LLC. ("CareXM"), a provider of virtual
care and patient engagement solutions for healthcare providers. Under the agreement CareXM has integrated
ECG monitoring capabilities through their TouchPointCare telemedicine platform.
CareXM has incorporated CardioComm's ECG viewer as an embedded technology in their TouchPointCare
platform to enable patients and physician clients to view ECGs while recording and to replay ECGs prior to
being uploaded for ECG reporting. Uploaded recordings will be processed by CardioComm's SMART
Monitoring ECG service and securely transmitted in near real-time to the CareXM TouchPointCare platform
where ECG reporting and patient care needs will be managed. Under the current deployment, patients will
utilize the HeartCheck™ CardiBeat to collect their ECGs under prescribed patient care protocols. CareXM and
CardioComm are examining the addition of 12 lead, Holter and arrhythmia/event monitoring devices and
expanding the capabilities of the TouchPoinCare platform to offer comprehensive outpatient and ambulatory
ECG monitoring. Sales and marketing of the ECG enabled TouchPointCare platform will be undertaken
exclusively by CareXM. CardioComm will see revenue from the sales of the HeartCheckT CardiBeat ECG
devices as well as from ECG service and triaging fees.
Through the addition of the GEMS™ technology, the TouchPointCare platform will be capable of recognizing
multiple ECG devices with up to 12 leads of ECG recording and provide customers with more options in
choosing a device of their preference. The HeartCheck™ CardiBeat will be the recommended device for selfdirected and prescribed remote arrhythmia monitoring and all recorded ECGs will be passed through
CardioComm's SMART Monitoring ECG service. The option for ECG triaging services to confirm the presence
or absence of an arrhythmia will be activated for any CareXM clients requesting the service. "We are excited
to advance our partnership with CardioComm," said Si Luo, CEO of CareXM, "with their advanced capabilities
in heart monitoring and CareXM's unique services-enabled next-gen RPM platform, we can keep putting home
care patients and their caregivers at the center of our focus by proactively anticipating a variety of care needs."
CareXM's patient engagement platform and virtual care offerings, including clinical nurse triage, are used by
home health and hospice providers, physician practices, hospitals, and many other care providers across the
United States. All services are HIPAA-compliant, available 24/7, and can be integrated with providers' existing
electronic medical record and scheduling platforms. The addition of ECG monitoring technologies into the
remote patient monitoring and health care platform follows CareXM's 2021 acquisition of TouchPointCare
and CareXM's partnership in 2020 with private equity firm DW Healthcare Partners.
To learn more about CardioComm's products and for further updates regarding HeartCheck™ ECG device integrations, please visit the Company's websites at
www.cardiocommsolutions.com and www.theheartcheck.com.
download pdf 
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and
storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a
combination of an external distribution network and a North American-based sales team. CardioComm Solutions has
earned the ISO 13485:2016 MDSAP certification, is HIPAA compliant and holds clearances from the European Union (CE
Mark), the USA (FDA) and Canada (Health Canada).
FOR FURTHER
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425
investor.relations@cardiocommsolutions.com
www.cardiocommsolutions.com
CareXM is HIPAA compliant provider of virtual care and patient engagement solutions for post-acute and nonacute
healthcare providers. CareXM's specialized service offerings include turnkey, remote patient monitoring (RPM)
technology and care management services solutions that support varying healthcare facilities including home health and
hospice, doctor and dental offices, and hospitals. CareXM is staffed with clinical nurses and non-clinical healthcare
professionals who are trained to help remotely manage patientsthrough appointment scheduling and medical answering
services, 24/7 nurse and telephone triage support, administrative office solution, secure instant messaging and physician
paging for urgent care issues. The CareXM platforms automatically connect patients directly to healthcare professionals
through proprietary virtual healthcare technology tools that is used to help health organizations to move to a proactive
and patient centric model to help improve patient care response times, reduce staff burden, and prevent unnecessary
patient hospital visits
CareXM Contact:
Sindy VonBank
US Director of RPM Business Development
Sindy.VonBank@CareXM.com
Forward-looking
statements
This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
|
|
